Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) is an American pharmaceutical company headquartered in New Haven, Connecticut, focused on developing novel therapies for neurological and immunological diseases. The company has built a significant pipeline targeting neurodegenerative disorders, particularly Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS)[1].
| Attribute | Value |
|---|---|
| Founded | 2013 |
| Headquarters | New Haven, Connecticut, USA |
| Ticker | NYSE: BHVN |
| CEO | Matthew Buten |
| Market Cap | ~$1.5B (2025) |
| Employees | ~300 |
| R&D Budget | ~$200M/year (2024) |
Biohaven was founded in 2013 as a spin-off company focused on developing novel CNS therapeutics. The company went public in 2017 on NASDAQ and transferred to NYSE in 2022[1:1].
Key milestones:
Biohaven's core technology platform focuses on Kv7.2/7.3 (KCNQ2/3) potassium channel activators[2]:
Biohaven is developing therapeutics targeting TDP-43 protein pathology:
| Drug | Mechanism | Stage | Status |
|---|---|---|---|
| BHVN-4151 (Troriluzole) | Kv7.2/7.3 activator | Phase 2 | Active |
| BHVN-7010 | Next-gen Kv7 activator | Phase 1 | Active |
| BHVN-3744 | TDP-43 modulator | Preclinical | Research |
Troriluzole in AD: Originally developed for epilepsy, troriluzole is being repurposed for AD based on preclinical data showing:
| Drug | Mechanism | Stage | Status |
|---|---|---|---|
| BHVN-4151 | Kv7 activator | Phase 2 | Active |
| BHVN-3744 | TDP-43 | Preclinical | Research |
Rationale: Kv7 modulators may protect dopaminergic neurons from:
| Drug | Mechanism | Stage | Status |
|---|---|---|---|
| Troriluzole (BHVN-4157) | Kv7.2/7.3 activator | Phase 3 | Completed enrollment |
| BHVN-3744 | TDP-43 | Preclinical | Research |
Phase 3 Trial (NCT04948645): Troriluzole was evaluated in patients with definite or probable ALS. Primary endpoint was survival or respiratory decline. Results expected 2025-2026[4].
Biohaven's approach to neurodegeneration:
| Year | Revenue | R&D Expenses | Cash Position |
|---|---|---|---|
| 2022 | $42M | $185M | $280M |
| 2023 | $58M | $210M | $265M |
| 2024 | ~$70M | ~$200M | ~$250M |
Biohaven competes with other pharmaceutical companies in the neurodegeneration space:
| Company | Key Programs | Mechanism |
|---|---|---|
| Amylyx | AMX0035 | UPR/PR activation |
| Cytokinetics | Reldesparlate | SOD1 aggregation |
| Biogen | Lecanemab, Aduhelm | Amyloid clearance |
| AbbVie | ABBV-951 | Gene therapy |
| Biohaven | Troriluzole, Kv7 | Ion channel modulation |
Biohaven Pharmaceutical Holding Company Ltd. Corporate information and pipeline. ↩︎ ↩︎
Milligan CJ, Li M, Gazina EV, et al. KCNQ2/3 channel activators as potential therapeutics for epilepsy and neurodegeneration. 2020. ↩︎ ↩︎
Rohn TT, Lin AW. TDP-43 in Alzheimer's disease: pathological mechanisms and therapeutic implications. 2023. ↩︎
Biohaven Pharmaceuticals. Troriluzole in Amyotrophic Lateral Sclerosis (ALS). ClinicalTrials.gov NCT04948645. ↩︎